Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 2

ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)

NCT06342947 · View on ClinicalTrials.gov ↗

Study Summary

This is a Phase 2a study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of oral (PO) daily (QD) doses of ALG-055009 (soft gelatin \[softgel\] capsule) for 12 weeks.

Interventions

  • DRUG Placebo
  • DRUG ALG-055009

Study Locations (20)

Florida

  • Aligos Clinical Study Site 26 — Bradenton
  • Aligos Clinical Study Site 25 — Clearwater
  • Aligos Clinical Study Site 39 — Fort Myers
  • Aligos Clinical Study Site 2 — Maitland
  • Aligos Clinical Study Site 22 — Ocoee
  • Aligos Clinical Study Site 32 — Port Orange
  • Aligos Clinical Study Site 38 — Sarasota
  • Aligos Clinical Study Site 31 — The Villages
  • Aligos Clinical Study Site 3 — Viera
  • Aligos Clinical Study Site 30 — Winter Park

California

  • Aligos Clinical Study Site 35 — Chula Vista
  • Aligos Clinical Study Site 1 — Lincoln
  • Aligos Clinical Study Site 37 — Poway
  • Aligos Clinical Study Site 10 — Rialto

Arizona

  • Aligos Clinical Study Site 18 — Chandler
  • Aligos Clinical Study Site 15 — Peoria
  • Aligos Clinical Study Site 17 — Tucson

Georgia

  • Aligos Clinical Study Site 23 — Athens

Kansas

  • Aligos Clinical Study Site 12 — Topeka

Kentucky

  • Aligos Clinical Study Site 29 — Louisville

Trial Details

FieldValue
Enrollment Target 102 participants
Start Date 2024-04-01
Est. Completion 2024-09-09
Phase Phase 2

Sponsor

Aligos Therapeutics

6 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06342947

The ClinicalTrials.gov registry entry for NCT06342947 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aligos Therapeutics, which has 6 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 4 conditions, with Nonalcoholic Steatohepatitis appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06342947 reports 20 study locations spanning 6 distinct geographic areas — top geographies include Florida, California, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06342947 about?

NCT06342947 is a clinical study titled "ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)". This is a Phase 2a study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of oral (PO) daily (QD) doses of ALG-055009 (soft gelatin \[softgel\] capsule) for 12 weeks.

What is the current status of trial NCT06342947?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2024-04-01. Estimated completion is 2024-09-09.

What conditions does trial NCT06342947 study?

This clinical trial studies the following conditions: Nonalcoholic Steatohepatitis, NASH, MASH, Metabolic Dysfunction-Associated Steatohepatitis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06342947?

The interventions under investigation include: Placebo (DRUG), ALG-055009 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06342947?

This trial is sponsored by Aligos Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06342947 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial